semaglutide cardiovascular outcomes 2025 news today align more closely with attained dose than achieved weight loss Semaglutide 2.4 mg delivered a

EDEN EDEN is a telehealth leader in the metabolic health space, offering prescription and personalized medications designed to improve health, support weight loss, and boost energy

The number of bariatric surgeries fell 8.7% in the last six months of 2023 compared with the same period in 2022 while the number of patients prescribed GLP-1 drugs rose 105.7% in the same time frame, according to a study in JAMA

For the first time in my life, I can eat responsibly

As you know, chronic inflammation can contribute to issues increasing feeling cold often ( 14 , 3 , 4 , 15 , 5 , 6 )

Retatrutide is an investigational triple agonist that targets three incretin and metabolic receptors simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors